lipoxin a4 and Body Weight

lipoxin a4 has been researched along with Body Weight in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gu, Y; Lu, J; Qin, Y; Song, Z; Wei, J; Xiong, Y; Zhu, Y1
Guo, YP; Jiang, H; Jiang, HK; Li, L; Tian, HY1
Bajaj, M; Birnbaum, Y; Gutierrez, AD; Konduru, S; Sathyanarayana, P; Ye, Y1

Trials

1 trial(s) available for lipoxin a4 and Body Weight

ArticleYear
The effect of pioglitazone treatment on 15-epi-lipoxin A4 levels in patients with type 2 diabetes.
    Atherosclerosis, 2012, Volume: 223, Issue:1

    Topics: Adiponectin; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Administration Schedule; Fatty Acids, Nonesterified; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipoxins; Male; Middle Aged; Pioglitazone; Texas; Thiazolidinediones; Time Factors; Treatment Outcome; Up-Regulation

2012

Other Studies

2 other study(ies) available for lipoxin a4 and Body Weight

ArticleYear
Effect of chiropractic manipulation on disrupted epithelium barrier and its mechanism of specialized pro-resolving mediators in a spleen-deficiency murine model.
    Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2019, Volume: 39, Issue:5

    Topics: Animals; Arachidonic Acid; Body Weight; Docosahexaenoic Acids; Epithelium; Gene Expression Regulation; Interferon-gamma; Interleukin-4; Jejunum; Lipoxins; Lung; Male; Manipulation, Chiropractic; Rats; Rats, Sprague-Dawley; RNA, Messenger; Spleen; Zonula Occludens-1 Protein

2019
Lipoxin A4 may attenuate the progression of obesity-related glomerulopathy by inhibiting NF-κB and ERK/p38 MAPK-dependent inflammation.
    Life sciences, 2018, Apr-01, Volume: 198

    Topics: Animals; Body Weight; Diet, High-Fat; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Extracellular Signal-Regulated MAP Kinases; I-kappa B Proteins; Inflammation; Injections, Intraperitoneal; Kidney Diseases; Kidney Glomerulus; Lipoxins; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; NF-kappa B; Obesity; p38 Mitogen-Activated Protein Kinases; Risk Factors

2018